Peeters Andrea

van Gestel Aukje, Webers Carroll A B, Beckers Henny J M, Peeters Andrea, Severens Johan L, Schouten Jan S A G

This study modeled ocular hypertension, finding the 15-year risk of unilateral blindness is under 10% for both treated and untreated patients, informing clinical management decisions.

Peeters Andrea, Schouten Jan S A G, Severens Johan L, Hendrikse Fred, Prins Martin H, Webers Carroll A B

This study found starting ocular hypertension treatment with timolol was more cost-effective than latanoprost for preventing blindness, due to latanoprost's higher cost.

Peeters Andrea, Webers Carroll A B, Prins Martin H, Hendrikse Fred, Schouten Jan S A G

Simulating initial timolol vs. latanoprost for ocular hypertension showed both strategies similarly lowered IOP and prevented blindness, suggesting initial drug choice has minimal long-term impact due to target-pressure guided adjustments.

Peeters Andrea, Webers Carroll A B, Prins Martin H, Zeegers Maurice P, Hendrikse Fred, Schouten Jan S A G

IOP reduction significantly lowers glaucoma conversion risk in ocular hypertension, with greater IOP lowering yielding more protection, emphasizing its clinical importance.